Editorial commentary: HIV treatment decisions and transmitted drug resistance

Clinical Infectious Diseases

Volumn 41, Issue 2, 2005, Pages 233-235

  Little, Susan J ^a,b   Smith, Davey M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; METHODOLOGY; NONHUMAN; NOTE; POPULATION RISK; PRIORITY JOURNAL; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION; DISEASE TRANSMISSION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTIDRUG RESISTANCE; VIROLOGY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 21844470461     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431215     Document Type: Note

References (28)

1. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1 [see comments]. N Engl J Med 1993; 328: 1163-5.
2. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
3. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-8.
4. Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev 2003; 5:140-55.
5. Simon V, Vanderhoeven J, Hurley A, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16:1511-9.
6. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-92.
7. de Mendoza C, Rodriguez C, Maria Eiros J, et al. Antiretroviral recommendations may influence the rate of transmission of drug-resistant viruses. Clin Infect Dis 2005; 41: 227-32 (in this issue).
8. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. International AIDS Society-USA. JAMA 1996;276:146-54.
9. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-65.
10. Nolan D, Mallal S. Complications associated with NRTI therapy, update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004; 9:849-63.
11. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2003; 2:624-34.
12. Liuzzi G, Chirianni A, Zaccarelli M, et al. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay. In Vivo 2004; 18:509-12.
13. Tirado G, Jove G, Reyes E, et al. Differential evolution of cell-associated virus in blood and genital tract of HIV-infected females undergoing HAART. Virology 2005; 334:299-305.
14. Quinn T, Wawer M, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342:921-9.
15. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium [see comments]. N Engl J Med 1998; 339:1897-904.
16. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-401.
17. Leigh Brown AJ, Frost SD, Mathews WC, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187:683-6.
18. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
19. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287: 650-4.
20. Yerly S, Jost S, Telenti A, et al. Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther 2004; 9:375-84.
21. de Mendoza C, Rodriguez C, Corral A, del Romero J, Gallego O, Soriano V. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. Clin Infect Dis 2004; 39: 1231-8.
22. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HFV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37:1570-3.
23. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18: 1683-9.
24. Delaugerre C, Morand-Joubert L, Chaix ML, et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004; 9: 415-21.
25. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005; 40: 468-74.
26. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-80.
27. Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365:1031-8.
28. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-28.